ReviewIntestinal research2020
Fibrostenotic strictures in Crohn's disease.
Review in Intestinal research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Risk Factors and Predictive Biomarkers for Postoperative Complications in Crohn's Disease Surgery: Systematic Review.International journal of molecular sciences · 2026Pooled it
- Efficacy and Safety of Endoscopic Stricturotomy in Inflammatory Bowel Disease-Related Strictures: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2024Pooled it
- Development of a Claims-Based Algorithm and Validation Through Medical Chart Review to Identify Patients with Crohn's Disease-Related Fibrostenosis: A Retrospective Observational Study in the United States.Advances in therapy · 2026Article
- Phenotypic Heterogeneity in Crohn's Disease-Associated Intestinal Strictures: An Exploratory Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- From inflammation to fibrosis and cancer: the emerging role of AIEC-derived metabolites in intestinal disease progression.Experimental & molecular medicine · 2026Review
- Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease.The Journal of pathology · 2026Article
- TET1 deficiency amplifies macrophage inflammatory signaling associated with Crohn's disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Characterizing Muscle Components in Intestinal Strictures Using Spectroscopic Photoacoustic Imaging.Journal of biophotonics · 2026Article
- Analysis of Periostin, TGF-β, and SLUG Expression in Inflammatory Bowel Disease in Pediatric Patients and Their Clinical Implications.Journal of clinical medicine · 2026Article
- Elucidating a Myofibroblast-dominated Fibrotic Niche in Crohn's Disease-associated Fibrostenosis Through High-resolution Spatial Transcriptomics.Cellular and molecular gastroenterology and hepatology · 2026Article
- Cellular senescence in Crohn's disease: a double-edged sword in intestinal fibrosis.Frontiers in immunology · 2026Review
- A model for Crohn's disease post-ileal resection fibrosis development using human ileal enteroids and myofibroblasts.Frontiers in physiology · 2026Article
- Myofibroblast-Driven Crohn's Disease Fiber Stricture Fibrotic Microenvironment: High-Resolution Spatial Transcriptomic Analysis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Beyond inflammation: what drives the self-perpetuating cycle of fibrosis in IBD?Annals of medicine · 2025Review
- Tolerability and effect of inhibiting microfibrillar-associated protein 4 in small intestinal anastomotic healing.Scientific reports · 2025Article
- Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn's disease.BMC gastroenterology · 2025Article
- Insights into the Molecular Mechanisms and Novel Therapeutic Strategies of Stenosis Fibrosis in Crohn's Disease.Biomedicines · 2025Review
- Molecular Basis of Chronic Intestinal Wall Fibrosis in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Review
- Disease-Specific Novel Role of Growth Differentiation Factor 15 in Organ Fibrosis.International journal of molecular sciences · 2025Review
- ECM formation and degradation during fibrosis, repair, and regeneration.npj metabolic health and disease · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn's disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still eventually undergo surgery mainly due to fibrostenotic strictures. There are no specific anti-fibrotic drugs yet. This review comprehensively addresses the mechanism, prediction, diagnosis and treatment of the fibrostenotic strictures in CD. We also introduce promising anti-fibrotic agents which may be available in the near future and summarize challenges in developing novel therapies to treat fibrostenotic strictures in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.